Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - (tablet core) budesonide micronized - tablet, film coated, extended release - (tablet core) budesonide micronized 9.0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; hypromellose; magnesium stearate; croscarmellose sodium; sucrose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate sandoz is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes. fenofibrate sandoz is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenofibrate sandoz does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; sucrose; hypromellose; docusate sodium; magnesium stearate; colloidal anhydrous silica; crospovidone; indigo carmine aluminium lake; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; quinoline yellow aluminium lake; xanthan gum; polyvinyl alcohol; lecithin - lipidil is indicated as an adjunct to diet in the treatment of: hypercholesterolaemia; types ii, iii, iv and v dislipidaemia; dyslipidaemia associated with type 2 diabetes. lipidil is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. lipidil does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium lauryl sulfate; crospovidone; hypromellose; magnesium stearate; lactose monohydrate; docusate sodium; microcrystalline cellulose; sucrose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - lipidil is indicated as an adjunct to diet in the treatment of: hypercholesterolaemia; types ii, iii, iv and v dislipidaemia; dyslipidaemia associated with type 2 diabetes. lipidil is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. lipidil does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: docusate sodium; hypromellose; sodium lauryl sulfate; sucrose; silicified microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenocol is indicated as an adjunct to diet in the treatment of:,? hypercholesterolaemia;,? types ii, iii, iv and v dyslipidaemia;,? dyslipidaemia associated with type 2 diabetes,fenocol is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenocol does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - minoxidil, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 1 january 1991 : indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil (loniten) has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - budesonide, quantity: 9 mg - tablet, modified release - excipient ingredients: stearic acid; lecithin; microcrystalline cellulose; hyprolose; lactose monohydrate; silicon dioxide; magnesium stearate; methacrylic acid copolymer; purified talc; titanium dioxide; triethyl citrate - cortiment prolonged-release tablets are indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis (uc) where 5-asa treatment is not sufficient or not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 35.125 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; magnesium stearate; calcium hydrogen phosphate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 25 mg tablets is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 140.5 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: hypromellose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 100 mg tablets is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 140.5 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; hypromellose; magnesium stearate; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 100 mg tablets is not indicated for use by women.